Gluten Challenge in Celiac Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02464150|
Recruitment Status : Recruiting
First Posted : June 8, 2015
Last Update Posted : July 14, 2020
Up till 30 participants with celiac disease on a glutenfree diet are asked to consume gluten containing cookies or bread for 3 days.
Questionnaires and sampling of blood is done before, during and after.
|Condition or disease||Intervention/treatment||Phase|
|Celiac Disease||Dietary Supplement: Gluten challenge||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Gluten Challenge in Celiac Disease|
|Actual Study Start Date :||April 1, 2017|
|Estimated Primary Completion Date :||August 2028|
|Estimated Study Completion Date :||August 2028|
Participants are subjected to gluten intervention in an unblinded fashion.
Dietary Supplement: Gluten challenge
Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
- Transcriptome of gluten-specific T cells [ Time Frame: Day 6 ]Transcriptional differences of glutenspecific vs. unspecific T cells
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02464150
|Contact: Stephanie Zühlke, MD||23074224 ext +email@example.com|
|Oslo university hospital - Rikshospitalet||Recruiting|
|Oslo, Norway, 0372|
|Contact: Stephanie Zühlke, M.D. firstname.lastname@example.org|
|Principal Investigator:||Knut EA Lundin, MD PhD||Oslo University Hospital and University of Oslo|